Thymic hyperplasia (TH) (figures 1, 2) occurs in autoimmune endocrine diseases such as Graves' disease (GD) and Addison's disease (AD) and is possibly related to its role in autoimmunity. Its true incidence is not known as thymic imaging is not undertaken routinely, and TH is usually diagnosed as a "thymic incidentaloma" in these conditions. We present 3 subjects with TH complicating GD and AD, who were managed expectantly, without intervention.
Subject
(a) Free T3 -6.7; free T4 18.7; TSH < 0.02 (b) TRAb -4.5 (c) CTPA ABNORMAL (similar appearances to Fig 1a, 2a) 
GD and AD, presenting with hypercalcaemia
Clinically and biochemically stable on carbimazole, hydrocortisone and fludrocortisone
GD -thoracic surgery postponed
Stable on carbimazole
GD -T3 toxicosis

Stable on carbimazole
Figure 2b (1) Thymic hyperplasia in GD, is benign in the vast majority -CT scan appearances are helpful in differentiating between benign and malignant enlargement (Box 1) (2) There is evidence that the thymus regresses in the majority after treatment of GD (3) Interval scanning should be done several months after control of thyrotoxicosis (4) Two of our subjects had regression of their TH when GD was treated with thionamides ( Figures  1b and 2b) -the third awaits interval scanning (5) We recommend that TH in GD should be managed expectantly with interval scans after 6 months of thionamide therapy, if initial scans confirm a benign morphology (6) Major surgery may thus be avoided in these metabolically fragile subjects 
